Skip to main content
Premium Trial:

Request an Annual Quote

LifeCodexx to Expand Lab for Trisomy 21 Test

Premium

LifeCodexx of Konstanz, Germany, will expand its laboratory next year to provide sequencing capacity for its upcoming non-invasive prenatal diagnostic test for trisomy 21, its parent company GATC Biotech said last week.

This summer, LifeCodexx licensed a patent surrounding technology for the test from Sequenom. Under the five-year agreement, the companies will develop and launch next-gen sequencing-based tests to diagnose trisomy 21 and possibly other aneuploidies in Germany, Austria, Switzerland, and Lichtenstein first, and maybe in other countries later (CSN 8/17/2011).

In June, LifeCodexx said that it started a clinical validation study of the trisomy 21 test, involving 500 samples analyzed on the Illumina HiSeq 2000. At the time, it was planning to launch the test by the end of this year (CSN 6/29/2011).

Sequenom started offering its MaterniT21 Down syndrome test as a lab-developed test in 20 metropolitan areas in the US last month (CSN 10/19/2011).

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.